Developer docs
API playgroundTry for free, no card

Search company profiles

Coloplast Denmark

Full company profile

uuid0034g1f

Namestring
Coloplast Denmark
Legal namestring
Coloplast Danmark A/S
Websiteurl
coloplast.dk
Company typeenum
Public
Founded yearint
1954
Descriptiontext

Coloplast Denmark A/S is the Danish operating subsidiary of Coloplast A/S, a publicly listed (Nasdaq Copenhagen: COLO-B) medical device group headquartered in Humlebæk, Denmark, and founded in 1954. The company develops and markets products and services for people with ostomy, continence, urological, and wound care needs, serving patient end-users, healthcare professionals (district nurses, wound care specialists), and Danish municipalities that authorize product coverage under the Serviceloven §112 Fritvalgsordningen (Free Choice Scheme).

The product portfolio spans four segments: ostomy care (SenSura Mio 1-piece and 2-piece systems, including the SenSura Mio Black line), continence care (SpeediCath hydrophilic-coated catheters, Luja with Micro-hole Zone Technology, SpeediCath Navi with flexible ball tip, Peristeen transanal irrigation, Conveen uridoms), wound care (Biatain silicone/foam/ag dressings, Comfeel Plus, alginate dressings, and the acquired Kerecis fish-skin biologic platform), and interventional urology. Key proprietary technologies include the uniform hydrophilic catheter coating enabling ready-to-use sterile catheterization, micro-hole zone geometry designed to reduce urinary tract infections and achieve complete bladder emptying, and intact fish-skin grafts validated by the Odinn randomized controlled trial (44% wound healing at 16 weeks vs 26.4% standard of care).

Coloplast makes money primarily through medical device product sales, with a recurring subscription-like model driven by chronic patient consumption. Products are paid for either directly by patients via credit card or MobilePay, or by Danish municipalities under the Fritvalgsordningen with home delivery via GLS. Group-level revenue is approximately $4.13 billion USD, with FY 2025/26 guidance of 5-6% organic growth and approximately 5% EBIT growth at constant exchange rates (lowered from ~7% due to Kerecis challenges). The Danish entity operates with a sales-led motion combining healthcare professional recommendation networks, a direct-to-consumer webshop, and municipal reimbursement integration.

Short descriptiontext

Coloplast Denmark A/S is the Danish subsidiary of Coloplast A/S, a publicly listed medical device group developing and selling ostomy bags, hydrophilic catheters, advanced wound dressings, and urology products for patients and healthcare professionals across Denmark and global markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersHumlebæk, Denmark
HQ citystring
Humlebæk
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ostomy care products, continence care devices, advanced wound care, intermittent catheters, medical device manufacturing
Industry3 codes
PRIMARYHLAHALAG
Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHSABAKAH
Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies)
Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services
SECONDARYCRAOAHAE
Medical Supplies & Consumables Wholesale (Non-Device)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ostomy and Continence Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical device product sales
TypeHardware Sales
Description

Coloplast generates revenue through the sale of medical devices including ostomy products, continence products (catheters), wound care products, and urology products. Products are sold to end-users (patients) directly or through municipal/insurance coverage systems, as well as through healthcare institutions.

defenseworld.net
2Government/insurance reimbursed products
TypeSubscription Recurring
Description

Products are partially or fully reimbursed through Danish municipal coverage (Sundhedsloven §112) for qualifying patients. Customers with prescriptions/authorizations receive products with municipal payment, creating a recurring revenue stream based on patient need.

produkter.coloplast.dk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details1 tier
1Products covered by municipal authorization (Fritvalgsordningen)
ModelSubscriptionBilling cadenceMonthly
Notes

Customers with municipal authorization receive products where the municipality pays directly. Customers purchasing products outside authorization or with partial coverage pay via credit card or MobilePay after receiving payment link.

produkter.coloplast.dk
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1SenSura Mio
Description

Ostomy bag product line including 1-piece and 2-piece systems

coloplast.dk
+6 more records
Core offering1 text field

Coloplast Denmark develops, manufactures, and markets medical devices for ostomy care, continence care, wound care, and interventional urology. Core products include hydrophilic-coated intermittent catheters (SpeediCath, Luja), ostomy bags and barriers (SenSura Mio), advanced wound dressings (Biatain), uridoms (Conveen), and transanal irrigation systems (Peristeen). Products are sold to patients directly through a webshop, via municipal reimbursement under the Danish Fritvalgsordningen (Free Choice Scheme), and through healthcare professional recommendations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Complete bladder emptying defined as <10ml residual
+2 more records
Product and service2 records
1SenSura Mio Ostomy Bags
CategoryOstomy Care
Description

One-piece and two-piece ostomy bags and barriers for people with colostomy, ileostomy, or urostomy. Designed to manage stoma output discreetly, prevent leakage, and protect peristomal skin. Available in standard and black variants with Click and Flex coupling systems.

2SpeediCath Hydrophilic Catheters
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical devices incumbent with material advanced wound care franchise (Allevyn, PICO) competing with Coloplast's Biatain portfolio and Kerecis biologic platform.

TypeDirect peer
Description

Direct competitor in ostomy care and continence care, and one of the three global leaders in ostomy dressings alongside Coloplast and ConvaTec. Privately held with overlapping product portfolios across stoma and continence.

TypeEmerging player
Description

Wholly-owned Coloplast subsidiary acquired from PAI Partners for EUR 2,155M; included as a peer reference because the laryngectomy franchise is a distinct intimate-healthcare vertical that benchmarks against other voice prosthesis players such as InHealth Technologies.

TypeDirect peer
Description

Direct competitor in intermittent catheters (LoFric) and bowel irrigation (Navina), competing head-to-head with Coloplast's SpeediCath and Peristeen franchises. Owned by Mölnlycke Health Care.

TypeBroad incumbent
Description

Larger wound care and surgical solutions player owning Wellspect; competes with Coloplast's Biatain advanced wound dressings and indirectly through its catheter subsidiary in Coloplast's core franchises.

TypeBroad incumbent
Description

Major medical device incumbent with a urology franchise (interventional stone management, pelvic health) that overlaps with Coloplast's interventional urology segment, particularly for surgical meshes and erectile dysfunction treatment.

TypeDirect peer
Description

Direct global competitor in ostomy care, continence care, and advanced wound care. ConvaTec is one of the three market leaders in ostomy dressings alongside Coloplast and Hollister, with overlapping hospital and home distribution channels.

TypeBroad incumbent
Description

Diversified medical device leader with a urology and pelvic health franchise that intersects with Coloplast's interventional urology segment, although Medtronic operates across a much broader device portfolio.

TypeBroad incumbent
Description

Large diversified medical device and infusion solutions company with an Actreen catheter line competing in intermittent self-catheterization and broader urology supplies overlapping with Coloplast's SpeediCath.

TypeBroad incumbent
Description

Broad incumbent in wound care and skin health (3M Tegaderm, V.A.C. therapy) that competes with Coloplast's Biatain advanced wound dressings across hospital and home care settings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coloplast Denmark

Ostomy and Continence Medical Devicescoloplast.dk

Coloplast Denmark A/S is the Danish subsidiary of Coloplast A/S, a publicly listed medical device group developing and selling ostomy bags, hydrophilic catheters, advanced wound dressings, and urology products for patients and healthcare professionals across Denmark and global markets.

What Coloplast Denmark does

Coloplast Denmark A/S is the Danish operating subsidiary of Coloplast A/S, a publicly listed (Nasdaq Copenhagen: COLO-B) medical device group headquartered in Humlebæk, Denmark, and founded in 1954. The company develops and markets products and services for people with ostomy, continence, urological, and wound care needs, serving patient end-users, healthcare professionals (district nurses, wound care specialists), and Danish municipalities that authorize product coverage under the Serviceloven §112 Fritvalgsordningen (Free Choice Scheme).

The product portfolio spans four segments: ostomy care (SenSura Mio 1-piece and 2-piece systems, including the SenSura Mio Black line), continence care (SpeediCath hydrophilic-coated catheters, Luja with Micro-hole Zone Technology, SpeediCath Navi with flexible ball tip, Peristeen transanal irrigation, Conveen uridoms), wound care (Biatain silicone/foam/ag dressings, Comfeel Plus, alginate dressings, and the acquired Kerecis fish-skin biologic platform), and interventional urology. Key proprietary technologies include the uniform hydrophilic catheter coating enabling ready-to-use sterile catheterization, micro-hole zone geometry designed to reduce urinary tract infections and achieve complete bladder emptying, and intact fish-skin grafts validated by the Odinn randomized controlled trial (44% wound healing at 16 weeks vs 26.4% standard of care).

Coloplast makes money primarily through medical device product sales, with a recurring subscription-like model driven by chronic patient consumption. Products are paid for either directly by patients via credit card or MobilePay, or by Danish municipalities under the Fritvalgsordningen with home delivery via GLS. Group-level revenue is approximately $4.13 billion USD, with FY 2025/26 guidance of 5-6% organic growth and approximately 5% EBIT growth at constant exchange rates (lowered from ~7% due to Kerecis challenges). The Danish entity operates with a sales-led motion combining healthcare professional recommendation networks, a direct-to-consumer webshop, and municipal reimbursement integration.

Coloplast Denmark firmographics

Firmographics
Name
Coloplast Denmark
Legal name
Coloplast Danmark A/S
Website
https://coloplast.dk
Company type
Public
Founded year
1954
Operating status
Operating
Headcount range
10,001+ employees
Short description
Coloplast Denmark A/S is the Danish subsidiary of Coloplast A/S, a publicly listed medical device group developing and selling ostomy bags, hydrophilic catheters, advanced wound dressings, and urology products for patients and healthcare professionals across Denmark and global markets.
Ownership category
akta.pro rank

Coloplast Denmark industry classification

Industry
Product category
Ostomy and Continence Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAG
Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHSABAKAH
Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies)
Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services
SECONDARYCRAOAHAE
Medical Supplies & Consumables Wholesale (Non-Device)

Keywords

  • Ostomy care products
  • Continence care devices
  • Advanced wound care
  • Intermittent catheters
  • Medical device manufacturing

Where Coloplast Denmark is headquartered

Location

Headquarters

HQ city
Humlebæk
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Coloplast Denmark business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Medical device product sales: Coloplast generates revenue through the sale of medical devices including ostomy products, continence products (catheters), wound care products, and urology products. Products are sold to end-users (patients) directly or through municipal/insurance coverage systems, as well as through healthcare institutions.
  2. Government/insurance reimbursed products: Products are partially or fully reimbursed through Danish municipal coverage (Sundhedsloven §112) for qualifying patients. Customers with prescriptions/authorizations receive products with municipal payment, creating a recurring revenue stream based on patient need.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyProducts covered by municipal authorization (Fritvalgsordningen)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Coloplast Denmark product offering

Product offering

Core offering

Coloplast Denmark develops, manufactures, and markets medical devices for ostomy care, continence care, wound care, and interventional urology. Core products include hydrophilic-coated intermittent catheters (SpeediCath, Luja), ostomy bags and barriers (SenSura Mio), advanced wound dressings (Biatain), uridoms (Conveen), and transanal irrigation systems (Peristeen). Products are sold to patients directly through a webshop, via municipal reimbursement under the Danish Fritvalgsordningen (Free Choice Scheme), and through healthcare professional recommendations.

Differentiator

Problem solved

Functional benefit

Brands

  • SenSura Mio: Ostomy bag product line including 1-piece and 2-piece systems
  • SpeediCath
  • Biatain
  • Conveen
  • Luja
  • Peristeen
  • Fritvalgsordningen Coloplast

Products and services

  • SenSura Mio Ostomy Bags One-piece and two-piece ostomy bags and barriers for people with colostomy, ileostomy, or urostomy. Designed to manage stoma output discreetly, prevent leakage, and protect peristomal skin. Available in standard and black variants with Click and Flex coupling systems.
  • SpeediCath Hydrophilic Catheters

Quantifiable outcome

  • Complete bladder emptying defined as <10ml residual
  • +2 more outcomes

Companies that use Coloplast Denmark

Customer profile

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Coloplast Denmark technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Coloplast Denmark partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Coloplast Denmark competitors and assessment

Company assessment

Broad incumbents

  • Smith+Nephew: Global medical devices incumbent with material advanced wound care franchise (Allevyn, PICO) competing with Coloplast's Biatain portfolio and Kerecis biologic platform.
  • Mölnlycke Health Care: Larger wound care and surgical solutions player owning Wellspect; competes with Coloplast's Biatain advanced wound dressings and indirectly through its catheter subsidiary in Coloplast's core franchises.
  • Boston Scientific: Major medical device incumbent with a urology franchise (interventional stone management, pelvic health) that overlaps with Coloplast's interventional urology segment, particularly for surgical meshes and erectile dysfunction treatment.
  • Medtronic: Diversified medical device leader with a urology and pelvic health franchise that intersects with Coloplast's interventional urology segment, although Medtronic operates across a much broader device portfolio.
  • B. Braun: Large diversified medical device and infusion solutions company with an Actreen catheter line competing in intermittent self-catheterization and broader urology supplies overlapping with Coloplast's SpeediCath.
  • 3M Health Care: Broad incumbent in wound care and skin health (3M Tegaderm, V.A.C. therapy) that competes with Coloplast's Biatain advanced wound dressings across hospital and home care settings.

Direct peers

  • Hollister Incorporated: Direct competitor in ostomy care and continence care, and one of the three global leaders in ostomy dressings alongside Coloplast and ConvaTec. Privately held with overlapping product portfolios across stoma and continence.
  • Wellspect Healthcare: Direct competitor in intermittent catheters (LoFric) and bowel irrigation (Navina), competing head-to-head with Coloplast's SpeediCath and Peristeen franchises. Owned by Mölnlycke Health Care.
  • ConvaTec: Direct global competitor in ostomy care, continence care, and advanced wound care. ConvaTec is one of the three market leaders in ostomy dressings alongside Coloplast and Hollister, with overlapping hospital and home distribution channels.

Emerging players

  • Atos Medical: Wholly-owned Coloplast subsidiary acquired from PAI Partners for EUR 2,155M; included as a peer reference because the laryngectomy franchise is a distinct intimate-healthcare vertical that benchmarks against other voice prosthesis players such as InHealth Technologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Coloplast Denmark social profiles

Digital presence

Coloplast Denmark financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coloplast Denmark leadership team

Management profile

Number of profiles

Profiles5 records

Coloplast Denmark subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Coloplast Denmark funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coloplast Denmark M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coloplast Denmark

What does Coloplast Denmark do?

Coloplast Denmark develops, manufactures, and markets medical devices for ostomy care, continence care, wound care, and interventional urology. Core products include hydrophilic-coated intermittent catheters (SpeediCath, Luja), ostomy bags and barriers (SenSura Mio), advanced wound dressings (Biatain), uridoms (Conveen), and transanal irrigation systems (Peristeen). Products are sold to patients directly through a webshop, via municipal reimbursement under the Danish Fritvalgsordningen (Free Choice Scheme), and through healthcare professional recommendations.

Is Coloplast Denmark a public or private company?

Coloplast Denmark is a public company. It is classified as public and is currently operating.

When was Coloplast Denmark founded?

Coloplast Denmark was founded in 1954. It employs 10,001+ people.

Where is Coloplast Denmark based?

Coloplast Denmark is headquartered in Humlebæk, Denmark, in the Europe region.

How does Coloplast Denmark make money?

Two revenue lines are on record. Medical device product sales are the primary driver. The others are government/insurance reimbursed products.

Who are Coloplast Denmark's main competitors?

Broad incumbents on record are Smith+Nephew, Mölnlycke Health Care, Boston Scientific, Medtronic, B. Braun and 3M Health Care. Direct peers are Hollister Incorporated, Wellspect Healthcare and ConvaTec. Atos Medical is listed as an emerging player.

Does Coloplast Denmark have an API?

No public API is recorded for Coloplast Denmark.

What industry is Coloplast Denmark in?

Coloplast Denmark's product category is Ostomy and Continence Medical Devices. Its primary akta.pro industry code is HLAHALAG, Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection), with a secondary code of HSABAKAH, Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies). Its NAICS code is 339113 and its SIC code is 5047.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAnalyzing Coloplast A/S (OTCMKTS:CLPBY) and RxSight (NASDAQ:RXST)Coloplast A/S and RxSight are compared on valuation, earnings, and analyst ratings. Coloplast beats RxSight on 10 of 15 factors, with higher revenue and earnings, while RxSight has a lower P/E ratio and higher upside. Analysts favor RxSight due to its lower price-to-earnings ratio.Ticker ReportRxSight (NASDAQ:RXST) vs. Coloplast A/S (OTCMKTS:CLPBY) Head to Head AnalysisA head-to-head analysis compares RxSight and Coloplast A/S on institutional ownership, valuation, and profitability. Coloplast A/S beats RxSight on 10 of 15 factors, with higher revenue and earnings, while RxSight has a lower price-to-earnings ratio and a higher analyst price target of $8.17.American Banking and Market NewsHead to Head Analysis: Elutia (NASDAQ:ELUT) and Coloplast A/S (OTCMKTS:CLPBY)Coloplast A/S and Elutia are compared on valuation, profitability, and analyst ratings. Coloplast has higher revenue ($4.13B vs $12.29M) and earnings, while Elutia trades at a lower P/E ratio. Coloplast beats Elutia on 8 of 13 factors.BorsenColoplast Fonden er nu stiftet – får 18 mia. kr.Coloplast's main shareholder, Niels Peter Louis-Hansen, formally established a new owner fund on Thursday. The fund, backed by 18 billion kr, is intended to secure the medical company and its thousands of employees a stable base in Denmark.BorsenMilliard­fond går i luften - får 18 mia. kr.Coloplast's main shareholder, Niels Peter Louis-Hansen, formally established a new billion-fund on October 1, 2026. The fund, named Coloplast Fonden, is intended to secure the medical company and its thousands of employees a stable base in Denmark.Ticker ReportColoplast A/S (OTCMKTS:CLPBF) Stock Price Down 8.8% – Here’s What HappenedColoplast A/S shares fell 8.8% on Wednesday, trading as low as $62.30, down 96% from average daily volume. The company, a Danish medical device firm, specializes in intimate healthcare products. Its 50-day moving average is $65.60 and 200-day is $64.52.Ticker ReportComparing Coloplast A/S (OTCMKTS:CLPBY) and Escalon Medical (OTCMKTS:ESMC)MarketBeat conducted a comparative analysis of healthcare companies Coloplast A/S and Escalon Medical, evaluating their profitability, risk, analyst recommendations, and valuation metrics. The report concluded that Coloplast A/S outperformed Escalon Medical in 9 out of 11 factors, particularly regarding revenue scale and return on equity.AD HOC NEWSColoplast stock holds steady after strong third-quarter profit reboundColoplast reported an 82 percent surge in third-quarter profit to nearly DKK 1.5 billion for its 2025/2026 financial year, reversing a significant decline caused by a large write-down in the previous quarter. Despite this operational recovery and beating earnings expectations, the company's stock remains down nearly 20 percent year-to-date as investors digest the volatility. The strong performance highlights the resilience of Coloplast's core chronic-care business segments, including ostomy and continence care.Seeking AlphaColoplast A/S Non-GAAP EPS of DKK 6.55, revenue of DKK 7.26B; reaffirms FY 2026 outlookColoplast A/S reported Q3 Non-GAAP EPS of DKK 6.55 and revenue of DKK 7.26 billion, representing a 4.3% year-over-year increase. The company delivered 6% organic growth and 5% EBIT growth in constant currencies, with EBIT reaching DKK 1,929 million. Coloplast reaffirmed its full-year 2026 financial outlook.YahooColoplast AS (CLPBF) (Q3 2026) Earnings Call Highlights: Organic Growth Steady at 6% Amid US ...Coloplast reported steady 6% organic revenue growth and a 14% increase in adjusted diluted EPS for the first nine months of 2026, driven by strong performance in the US market and key product lines. The company highlighted robust free cash flow generation of DKK4.1 billion and announced full-year guidance targeting 5-6% organic revenue growth.